Supratentorial ICH — Trial Evidence

STICH (2005)

• Design: Early surgical evacuation (within 24h) vs. initial conservative treatment for spontaneous supratentorial ICH
• Result: No overall benefit of early surgery
• Subgroup signal: STICH 2005 showed a subgroup trend toward benefit for superficial lobar hematomas (depth from cortex ≤1 cm)
• Deep hemorrhages (basal ganglia, thalamus) showed no surgical benefit

STICH II (2013)

• Design: STICH II prospectively tested the STICH-2005 subgroup hypothesis, using the ≤1 cm cortical-depth criterion as entry (lobar ICH, 10–100 mL volume, no IVH)
• Result: Also negative for benefit overall — no statistically significant advantage of early surgery over conservative management
• Important caveat: 21% crossover from conservative to surgical group diluted the treatment effect
• Take-home: Even with the STICH-2005 subgroup criterion prospectively applied, routine early craniotomy for lobar ICH is NOT supported; surgery may benefit patients who deteriorate

MISTIE III (2019)

• Design: Minimally invasive surgery with stereotactic catheter + alteplase irrigation (to dissolve and drain clot) vs. standard medical care for ICH ≥30 mL
• Primary outcome: Did NOT meet endpoint (mRS 0–3 at 365 days)
• Critical secondary finding: Patients whose hematoma was reduced to <15 mL had significantly better outcomes
• Implication: The degree of clot removal matters — if sufficient evacuation is achieved, outcomes improve

ENRICH (2024)

• Design: Early minimally invasive parafascicular surgery (BrainPath device) + medical care vs. medical care alone. Initially enrolled both lobar AND anterior basal ganglia ICH (30–80 mL); the basal ganglia arm was stopped early for futility, and enrollment continued with lobar patients only
• Result: Met primary endpoint — improved utility-weighted mRS at 180 days, with benefit demonstrated in the LOBAR subgroup only
• First RCT to demonstrate benefit of surgical evacuation for supratentorial ICH
• Reinforces that technique and patient selection (lobar, accessible hematomas) are critical — deep ICH remains non-surgical

Cerebellar Hemorrhage — Surgical Emergency

• Posterior fossa is a confined space — even moderate-sized hemorrhages can cause rapid brainstem compression and death
• Surgical evacuation (suboccipital craniectomy) is indicated for:
  • Cerebellar ICH volume ≥15 mL (corresponds to the classic >3 cm diameter heuristic; 2022 AHA/ASA uses volume-based wording)
  • Neurological deterioration (declining GCS)
  • Brainstem compression (absent brainstem reflexes, new cranial nerve palsies, progressive obtundation)
  • Obstructive hydrocephalus from fourth ventricle compression
• 2022 AHA/ASA recommendation — immediate surgical evacuation, with or without EVD, is recommended for the criteria above; one of the most clear-cut surgical indications in neurology
• EVD alone is insufficient — does not address posterior fossa mass effect; must evacuate the clot
• Excellent outcomes are possible if surgery is performed before irreversible brainstem damage
• Small cerebellar hemorrhages (volume <15 mL, roughly <3 cm) without neurologic deterioration, brainstem compression, or hydrocephalus → medical management with close monitoring

General Indications for Surgical Consideration

• Deteriorating patient with accessible hematoma (lobar, superficial) despite maximal medical management
• Young patient with lobar ICH and good pre-morbid function
• Hematoma causing significant mass effect with midline shift and risk of herniation
• Underlying structural lesion identified (AVM, tumor, aneurysm) that requires surgical treatment

When NOT to Operate

• Deep hemorrhages (basal ganglia, thalamus) — surgical approach traverses eloquent tissue; no proven benefit
• Brainstem hemorrhage — not surgically accessible; devastating prognosis regardless
• Small ICH (<10 mL) with minimal or no neurological deficit — medical management is appropriate
• GCS 3–4 with bilateral fixed and dilated pupils — poor prognosis regardless of intervention (but consider goals of care)
• Large ICH (>60 mL) with GCS ≤8 — very high mortality; limited surgical benefit (controversial)

Indications for EVD

• Obstructive hydrocephalus from intraventricular hemorrhage (IVH) with acute neurological decline
• Posterior fossa mass effect (cerebellar hemorrhage compressing fourth ventricle)
• ICP monitoring in patients with GCS ≤8 and abnormal CT
• Therapeutic CSF drainage to reduce ICP
• Intraventricular thrombolysis (e.g., CLEAR III protocol — alteplase via EVD to lyse IVH)

Kocher’s Point — The Landmark

• Location: 1–2 cm anterior to the coronal suture, ~2.5–3 cm lateral to midline at the mid-pupillary line (approximately 11 cm posterior to the nasion)
• Target: Ipsilateral frontal horn of the lateral ventricle
• Trajectory: Catheter aimed toward the medial canthus of the ipsilateral eye in the coronal plane, and toward the tragus / external auditory meatus (EAM) in the sagittal plane
• Depth: Typically 5–7 cm from the cortical surface to reach the ventricle
• Side selection: Usually placed on the right (non-dominant hemisphere) unless hydrocephalus is asymmetric

EVD Management

• Set drainage height: 10–20 cmH₂O above the external auditory meatus (tragus) — the zero reference point
• Monitor ICP continuously: Target ICP <22 mmHg, CPP 60–70 mmHg
• Record CSF output hourly; notify if output drops suddenly (may indicate catheter obstruction or migration)
• Daily CSF sampling: Cell count, glucose, protein, Gram stain, culture — to monitor for ventriculitis
• Flush ONLY when catheter is obstructed — routine flushing increases infection risk

Complications

Weaning & Conversion to VP Shunt

• Weaning protocol: Gradually raise the EVD level by 5 cmH₂O increments over days
• Clamp trial: Clamp EVD for 24–48 hours; monitor for symptoms (headache, nausea, decreased alertness) and repeat CT to assess ventricle size
• If patient tolerates clamping without ICP elevation or ventricular enlargement → safe to remove EVD
• If patient cannot be weaned (fails clamp trial repeatedly, persistent ventriculomegaly) → VP shunt placement
• VP shunt needed in ~20% of patients with IVH-related hydrocephalus
• Ensure CSF is sterile before shunt placement (CSF WBC <10, negative cultures)

Indications (Brain Trauma Foundation 2016)

• GCS ≤8 (coma) with abnormal CT (hematoma, contusion, swelling, herniation, compressed basal cisterns)
• GCS ≤8 with normal CT if ≥2 of the following: age >40, unilateral or bilateral motor posturing, SBP <90 mmHg
• Clinical signs of elevated ICP or herniation where serial neurological exams are unreliable (sedated, paralyzed patients)
• Large ICH with mass effect, especially when surgical decision-making depends on ICP trends

Types of ICP Monitors

ICP Targets

• ICP target: <22 mmHg (Brain Trauma Foundation 2016 — updated from previous <20 threshold)
• CPP (Cerebral Perfusion Pressure) target: 60–70 mmHg
  • CPP = MAP – ICP
  • CPP <60 mmHg → increased risk of cerebral ischemia
  • CPP >70 mmHg → increased risk of ARDS (aggressive vasopressor use)
• Normal ICP: 5–15 mmHg in adults; <10 mmHg in children
• Sustained ICP >22 mmHg = intracranial hypertension requiring treatment

Lundberg Waves

CTA Spot Sign — Expansion Predictor

• Definition: One or more foci of active contrast extravasation within the hematoma on CTA source images
• Appears as 1–2 mm enhancing foci (density ≥120 HU) within the hematoma, discontinuous from normal vasculature
• Sensitivity ~50–60%, specificity ~85–90% for predicting hematoma expansion
• Number and size of spot signs correlate with expansion risk, need for intervention, and mortality
• Best detected on CTA source images or delayed-phase CTA (1–3 minutes post-injection)
• Other NCCT signs of impending expansion: blend sign (heterogeneous density), swirl sign, black hole sign, irregular hematoma shape

Blood Pressure Management

• Current target (2022 AHA/ASA ICH guideline): For mild-to-moderate ICH presenting with SBP 150–220 mmHg, target SBP ~140 with maintenance 130–150 is safe and may be reasonable; rapid reduction to <130 mmHg is NOT recommended (Class III: Harm) based on the ATACH-2 harm signal (achieved SBP ~129 → renal adverse events without functional benefit). Safety/efficacy are not well established for large/severe ICH or patients requiring surgical decompression
• Preferred agent: IV nicardipine (5 mg/hr, titrate by 2.5 mg/hr q5–15 min, max 15 mg/hr) for precise titration
• Avoid nitroprusside (raises ICP) and sublingual nifedipine (unpredictable drops)

Reversal of Anticoagulation

Platelet Transfusion — NOT Beneficial

• PATCH Trial (2016): Platelet transfusion in patients on antiplatelet agents with acute spontaneous supratentorial ICH
• Result: Platelet transfusion was associated with WORSE outcomes (higher odds of death or dependence at 3 months)
• Mechanism of harm: Likely platelet activation and prothrombotic/proinflammatory effects
• Recommendation: Platelet transfusion is NOT routinely recommended for antiplatelet-associated ICH; consider only if neurosurgical procedure is planned

Other Hemostatic Approaches

• Recombinant factor VIIa (rFVIIa): FAST trial — reduced hematoma expansion but increased thromboembolic events with no net clinical benefit; NOT recommended
• Tranexamic acid (TXA): TICH-2 trial (2018) — reduced hematoma expansion at 24h but no improvement in 90-day functional outcome; not routinely recommended

AED Prophylaxis — 2022 AHA/ASA

• Class III (No Benefit / Potential Harm): Routine prophylactic anti-epileptic drug (AED) use is NOT recommended in spontaneous ICH
• Treat only for: (1) clinical seizures, or (2) electrographic seizures detected on continuous EEG (cEEG)
• Levetiracetam is preferred if AED therapy is needed (favorable cognitive and interaction profile vs. phenytoin)
• cEEG monitoring is reasonable for ICH patients with depressed mental status out of proportion to imaging or with suspected non-convulsive status
• Phenytoin has been associated with worse outcomes in ICH cohorts — avoid as first-line prophylaxis

DVT Prophylaxis — Timing

• Mechanical prophylaxis: Intermittent pneumatic compression (IPC) immediately on admission — CLOTS-3 trial supports IPC for stroke patients; no hemorrhagic risk
• Graduated compression stockings alone are NOT recommended (CLOTS-1 showed no benefit, increased skin breakdown)
• Pharmacologic prophylaxis (LMWH or unfractionated heparin): typically delayed to 24–48 hours after documented hemorrhage stability on repeat imaging
• Confirm stability with NCCT before initiating pharmacologic prophylaxis; do not start in the setting of ongoing expansion
• Continue mechanical prophylaxis throughout the hospitalization until ambulation

Cavernous Malformations (Cavernomas)

• Low-flow vascular malformations composed of dilated sinusoidal vessels without intervening brain parenchyma; angiographically occult
• Classic MRI appearance: “popcorn” or “mulberry” lesion with a complete hemosiderin ring on T2/GRE/SWI (blooming artifact)
• Annual hemorrhage risk: ~0.6–1% per year in naïve (unruptured) lesions; rises to ~4–23% per year after a first hemorrhage (highest in the first 2 years, then decays)
• Familial form: CCM1 (KRIT1), CCM2, CCM3 (PDCD10) mutations — multiple lesions on imaging
• Management: Surgical resection for symptomatic, accessible (lobar/superficial) lesions, especially after symptomatic hemorrhage or refractory seizures; observe asymptomatic and deep/brainstem lesions
• Stereotactic radiosurgery may be considered for surgically inaccessible symptomatic lesions (controversial)

Pituitary Apoplexy

• Acute hemorrhage or infarction within a pituitary adenoma (usually a previously unrecognized macroadenoma)
• Classic tetrad: thunderclap headache + bitemporal hemianopsia (optic chiasm compression) + ophthalmoplegia (cavernous sinus involvement — CN III, IV, VI; CN III most common) + acute panhypopituitarism (adrenal crisis, hypothyroidism, hypogonadism)
• EMERGENT IV hydrocortisone 100 mg before imaging-directed intervention — do NOT wait for cortisol/ACTH results; adrenal insufficiency is the immediate killer
• MRI pituitary with contrast is the imaging study of choice (CT often misses small lesions)
• Transsphenoidal decompression if visual compromise, declining mental status, or worsening ophthalmoplegia despite steroids; conservative management acceptable if vision intact and patient stable
• Long-term endocrine follow-up is essential — most patients require lifelong hormone replacement

Dural Arteriovenous Fistula (dAVF)

• Acquired arteriovenous shunts within the dura (in contrast to congenital pial AVMs); often associated with prior dural sinus thrombosis, trauma, or surgery
• Most commonly involve the transverse-sigmoid sinus, cavernous sinus, or superior sagittal sinus
• Cortical venous reflux (CVR) = high-risk feature → markedly elevated risk of intracranial hemorrhage and non-hemorrhagic neurological deficit
• Classifications:
  • Borden I–III: based on venous drainage pattern (I = sinus only, no CVR; II = sinus + CVR; III = CVR only)
  • Cognard I–V: more granular — adds direction of flow, venous ectasia, and spinal perimedullary drainage
  • Higher grade = higher hemorrhage risk; Borden II–III / Cognard IIb–V warrant treatment
• Endovascular embolization (transarterial ± transvenous; Onyx or coils) is first-line treatment; surgical disconnection or stereotactic radiosurgery reserved for refractory or anatomically unfavorable lesions

Decision Table

• Step 1: Confirm ICH on NCCT; assess location, size, GCS, presence of IVH
• Step 2: Is this a cerebellar ICH with neurologic deterioration, brainstem compression, obstructive hydrocephalus, or volume ≥15 mL (classic >3 cm heuristic)?
  • YES → Emergent suboccipital craniectomy + clot evacuation + EVD if hydrocephalus. Do NOT delay
• Step 3: Is this a brainstem (pontine) hemorrhage?
  • YES → NOT a surgical candidate. Medical management only
• Step 4: Is this a deep ICH (putamen, thalamus, caudate)?
  • YES → Generally NOT surgical. Place EVD if IVH with hydrocephalus. Medical management
• Step 5: Is this a lobar ICH ≥30 mL within 1 cm of cortical surface?
  • Consider minimally invasive surgery (ENRICH approach) if available
  • Consider standard craniotomy if patient is deteriorating with accessible hematoma
• Step 6: Is there IVH with hydrocephalus?
  • YES → EVD placement at Kocher’s point. Consider intraventricular alteplase per CLEAR III protocol (after discussion of mortality vs. disability trade-off)
• Step 7: Is the patient on anticoagulation?
  • YES → Immediately reverse (4F-PCC for warfarin, idarucizumab for dabigatran, andexanet/4F-PCC for Xa inhibitors). Do NOT delay reversal for any reason
• Step 8: For mild-to-moderate ICH presenting with SBP 150–220 mmHg: target SBP ~140 with maintenance 130–150 mmHg (2022 AHA/ASA); avoid acute lowering below 130 mmHg (Class III: Harm per ATACH-2); evidence is less established for large/severe ICH or surgical decompression. ICU monitoring, ICP management as needed, repeat imaging at 6–24 hours